UVA Health Cancer Center researchers have developed an algorithm that will improve cancer care by quickly and easily identifying patients who will benefit from powerful cancer drugs called kinase inhibitors. The algorithm may have other diagnostic benefits for patients as well.
Kinase inhibitors are the most common cancer drugs approved by the federal Food and Drug Administration. They can be hugely effective for the right patients, but they don’t work for everyone. UVA’s new algorithm offers a new and better way to pinpoint patients who will benefit – an important step forward in precision medicine tailored to the individual.
“We are really excited about this algorithm, which performs better than existing approaches with fewer requirements and assumptions – making it more applicable to understanding a cancer state from a single snapshot of the tumor,” said researcher Kristen M. Naegle, PhD, of UVA’s Department of Biomedical Engineering, a joint program of UVA’s School of Medicine and School of Engineering. “Combining this approach with existing biomarkers for cancer diagnosis may help us to better tailor therapies, design new combination therapies, anticipate response to treatment and design better clinical trials.”
KSTAR for Better Cancer Care
Naegle and colleagues set out to overcome the limitations of existing methods to identify patients who may benefit from kinase inhibitors. Most of these methods require difficult-to-obtain and sometimes unreliable information quantifying “phosphorylation sites” within cells. UVA’s new approach, however, does not need all this complex measurement. Instead, it can “infer,” or predict, key information based on other available data. This allows the algorithm to produce a specific “KSTAR score” for individual enzymes called kinases. Doctors can use these scores to determine which patients will respond to kinase inhibitors, helping guide the best treatment choices.
In testing their new algorithm, Naegle and her collaborators found that it worked reliably across different tissue types, suggesting it is useful for many types of cancer. (Kinase inhibitors are widely used for certain types of blood, breast and lung cancers, among others. These drugs are often used in conjunction with other treatments, such as chemotherapy, radiation or surgery.)
As an added benefit, KSTAR can serve as a diagnostic tool, the UVA researchers report. During their tests, KSTAR was able to determine that a patient with breast cancer was not HER2 positive, as doctors had previously believed. HER2-positive breast cancers can benefit from HER2-targeted kinase inhibition, but HER2-negative tumors will not, and HER2-inhibition comes with additional complications. Additionally, the researchers find that around 20% of patients identified as HER2-negative by current clinical approaches actually have HER2 signatures that suggest they could benefit from HER2-targeted treatment – a treatment not currently offered to them. That type of information can be invaluable as doctors and patients discuss treatment options.
“We are collaborating and working with teams of researchers across a range of cancers to establish when and how KSTAR can help identify patient response to treatment,” Naegle said. “We hope that we will be able to help better identify the right treatment for the right patient at the right time for better outcomes for patients.”
Naegle and her collaborators have made their new algorithm freely available at https://github.com/NaegleLab/KSTAR. The work is part of UVA Health Cancer Center’s ongoing mission to find new and better ways to diagnose and treat cancer in all its forms.
UVA Health Cancer Center this year became one of only 52 cancer centers in the country designated as a Comprehensive Cancer Center by the National Cancer Institute. The designation recognizes elite cancer centers with the most outstanding cancer programs in the nation. Comprehensive Cancer Centers must meet rigorous standards for innovative research and leading-edge clinical trials.
UVA Health Cancer Center is the only Comprehensive Cancer Center in Virginia.
Naegle and her collaborators have published their findings in the journal Nature Communications. The team consisted of Sam Crowl, Ben T. Jordan, Hamza Ahmed, Cynthia X. Ma and Naegle.
The work was supported by the National Cancer Institute, grant R21CA231853.
To keep up with the latest medical research news from UVA, subscribe to the Making of Medicine blog at http://makingofmedicine.virginia.edu.